Zebra Capital Management Has Cut Stepan Co Com Stk (SCL) Holding; Mirati Therapeutics (MRTX) Has 1.17 Sentiment

January 14, 2018 - By Nellie Frank

Zebra Capital Management Llc decreased Stepan Co Com Stk (SCL) stake by 20.09% reported in 2017Q3 SEC filing. Zebra Capital Management Llc sold 5,091 shares as Stepan Co Com Stk (SCL)’s stock rose 6.46%. The Zebra Capital Management Llc holds 20,250 shares with $1.69 million value, down from 25,341 last quarter. Stepan Co Com Stk now has $1.79 billion valuation. The stock decreased 0.55% or $0.44 during the last trading session, reaching $79.31. About 156,380 shares traded or 115.58% up from the average. Stepan Company (NYSE:SCL) has risen 47.84% since January 14, 2017 and is uptrending. It has outperformed by 31.14% the S&P500.

Mirati Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of oncology products. The company has market cap of $690.80 million. The companyÂ’s clinical stage product candidates include glesatinib, an orally-bioavailable, potent, small molecule kinase inhibitor that is in Phase II clinical trials for the treatment of non-small cell lung cancer patients with genetic alterations of MET; and in Phase Ib clinical trials in patients with genetic alterations of MET and Axl in NSCLC and other solid tumors. It currently has negative earnings. The Company’s clinical stage product candidates also comprise sitravatinib, an orally-bioavailable, potent, small molecule spectrum-selective kinase inhibitor, which is in Phase II clinical trials for the treatment of solid tumors, such as NSCLC and metastatic Renal Cell Carcinoma, as well as in Phase Ib clinical trials to treat NSCLC patients with RET, CHR4q12, CBL, and AXL genetic alterations; and mocetinostat, an orally administered spectrum-selective Class 1 histone deacetylase inhibitor, which is in Phase Ib/II clinical trials in combination with durvalumab for the treatment of patients with NSCLC.

Among 7 analysts covering Stepan Co (NYSE:SCL), 4 have Buy rating, 0 Sell and 3 Hold. Therefore 57% are positive. Stepan Co had 12 analyst reports since August 26, 2015 according to SRatingsIntel. The firm has “Outperform” rating by National Bank Canada given on Monday, August 15. Seaport Global maintained Stepan Company (NYSE:SCL) rating on Wednesday, August 24. Seaport Global has “Neutral” rating and $70 target. The rating was maintained by KeyBanc Capital Markets with “Hold” on Friday, September 1. The firm has “Strong Buy” rating by Industrial Alliance Securities given on Monday, May 29.

Zebra Capital Management Llc increased Tjx Cos Inc New Com Stk (NYSE:TJX) stake by 4,258 shares to 20,586 valued at $1.52 million in 2017Q3. It also upped Mylan Inc Com Stk (NASDAQ:MYL) stake by 17,992 shares and now owns 46,759 shares. Enterprise Finl Svcs Corp Com (NASDAQ:EFSC) was raised too.

Since August 7, 2017, it had 0 insider purchases, and 7 selling transactions for $2.34 million activity. PACHOLEC FRANK sold $120,150 worth of Stepan Company (NYSE:SCL) on Friday, September 8. STEPAN F QUINN JR sold $1.19M worth of stock. Boyce Michael Ross sold $67,144 worth of stock. Behrens Scott R. had sold 667 shares worth $51,783. 8,865 shares valued at $713,633 were sold by STEPAN F QUINN on Monday, August 7.

Investors sentiment decreased to 1.03 in Q3 2017. Its down 0.38, from 1.41 in 2017Q2. It dropped, as 23 investors sold SCL shares while 56 reduced holdings. 21 funds opened positions while 60 raised stakes. 13.94 million shares or 0.54% more from 13.86 million shares in 2017Q2 were reported. Comerica State Bank has invested 0.01% in Stepan Company (NYSE:SCL). New Jersey-based Jacobs Levy Equity Management has invested 0.06% in Stepan Company (NYSE:SCL). Prelude Capital Limited Co invested in 3,650 shares or 0.03% of the stock. Dana Invest Advisors, a Wisconsin-based fund reported 26,065 shares. Hillcrest Asset Mngmt Limited Co stated it has 137,068 shares or 2.08% of all its holdings. Deutsche Financial Bank Ag holds 0% of its portfolio in Stepan Company (NYSE:SCL) for 22,816 shares. Tiaa Cref Investment Management Limited Company holds 0.01% of its portfolio in Stepan Company (NYSE:SCL) for 112,986 shares. Zurcher Kantonalbank (Zurich Cantonalbank) reported 647 shares. Art Advisors Limited Liability has invested 0.05% in Stepan Company (NYSE:SCL). Point72 Asia (Hong Kong) Ltd holds 0% or 11 shares in its portfolio. Goldman Sachs Grp Incorporated reported 0% of its portfolio in Stepan Company (NYSE:SCL). 2,723 are held by Amalgamated Comml Bank. Bessemer Grp Inc invested in 25,100 shares or 0.01% of the stock. Pnc Fincl Serv Grp Inc Inc holds 0% of its portfolio in Stepan Company (NYSE:SCL) for 2,343 shares. Millennium has invested 0.02% of its portfolio in Stepan Company (NYSE:SCL).

Analysts await Stepan Company (NYSE:SCL) to report earnings on February, 28. They expect $0.70 EPS, up 34.62% or $0.18 from last year’s $0.52 per share. SCL’s profit will be $15.76M for 28.33 P/E if the $0.70 EPS becomes a reality. After $0.92 actual EPS reported by Stepan Company for the previous quarter, Wall Street now forecasts -23.91% negative EPS growth.

Analysts await Mirati Therapeutics, Inc. (NASDAQ:MRTX) to report earnings on March, 8. They expect $-0.65 earnings per share, up 34.34% or $0.34 from last year’s $-0.99 per share. After $-0.65 actual earnings per share reported by Mirati Therapeutics, Inc. for the previous quarter, Wall Street now forecasts 0.00% EPS growth.

It closed at $24.75 lastly. It is down 76.51% since January 14, 2017 and is downtrending. It has underperformed by 93.21% the S&P500.

Since January 1, 0001, it had 0 buys, and 2 selling transactions for $65,240 activity.

Broadfin Capital Llc holds 4.31% of its portfolio in Mirati Therapeutics, Inc. for 2.49 million shares. Venbio Select Advisor Llc owns 3.71 million shares or 3.37% of their US portfolio. Moreover, Cormorant Asset Management Llc has 2.07% invested in the company for 1.00 million shares. The New York-based Baker Bros. Advisors Lp has invested 0.22% in the stock. Element Capital Management Llc, a New York-based fund reported 17,422 shares.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>